Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
Overview
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
Associated Conditions
- Kaposi's Sarcoma
- Multiple Myeloma (MM)
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
POMAGEN CAPSULES 3MG
Manufacturer:Lotus Pharmaceutical Co., Ltd. Nantou Plant
Form:CAPSULE
Strength:3.0 mg
Online:Yes
Approved: 2024/04/12
Approval:SIN16985P
POMAGEN CAPSULES 2MG
Manufacturer:Lotus Pharmaceutical Co., Ltd. Nantou Plant
Form:CAPSULE
Strength:2.0 mg
Online:Yes
Approved: 2024/04/12
Approval:SIN16984P
POMALYST CAPSULE 1MG
Manufacturer:Celgene International Sarl
Form:CAPSULE
Strength:1 mg
Online:Yes
Approved: 2014/12/30
Approval:SIN14713P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath